An Open-Label Expanded Access Protocol for Esketamine Treatment of Subjects With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
Latest Information Update: 18 Sep 2023
At a glance
- Drugs Esketamine (Primary)
- Indications Depression; Major depressive disorder
- Focus Adverse reactions; Expanded access
- Sponsors Janssen-Cilag
- 13 Sep 2023 Status changed from recruiting to completed.
- 28 Jun 2023 Planned End Date changed from 15 May 2023 to 30 Jun 2023.
- 28 Jun 2023 Planned primary completion date changed from 30 Apr 2023 to 30 Jun 2023.